If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-27. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
=== EC 1.7.2 With a cytochrome as acceptor === EC 1.7.2.1: nitrite reductase (NO-forming) EC 1.7.2.2: nitrite reductase (cytochrome; ammonia-forming) EC 1.7.2.3: trimethylamine-N-oxide reductase EC 1.7.2.4: nitrous-oxide reductase EC 1.7.2.5: nitric oxide reductase (cytochrome c) EC 1.7.2.6: hydroxylamine dehydrogenase EC 1.7.2.7: hydrazine synthase EC 1.7.2.8: hydrazine dehydrogenase
== Precautions and contraindications == Administration of tylosin should be avoided in animals with a known hypersensitivity to the product, or to other macrolides. Oral administration can result in diarrhoea and gastrointestinal disturbance. This is particularly true of horses, such that it can be fatal. Tylosin also has a foul taste that is difficult to disguise. The injectable formulations of tylosin can cause pain, inflammation, and itchiness around the injection site. Since tylosin has a relatively poor spectrum of activity against Gram-negative organisms, it may not be a sensible therapeutic choice in the treatment of infections caused by unknown, potentially unsusceptible organisms.
PL-6983 is a synthetic peptide and selective MC4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction. It was developed as a successor to/replacement of bremelanotide (PT-141) due to concerns of the side effect of increased blood pressure seen with the latter in clinical trials. Relative to bremelanotide, PL-6983 produces significantly lower increases in blood pressure in animal models. The drug has reportedly been in pre-clinical development for all medical indications since 2008. Palatin has stated that "We are focusing development efforts on bremelanotide for [female sexual dysfunction], but are continuing evaluation of PL-6983." The chemical structure of PL-6983 has yet to be made public.
While the band found success and critical acclaim, creative tensions were already developing. Giles and McDonald, still striving to cope with King Crimson's rapid success and the realities of touring life, became uneasy with their musical direction. Although he was neither the dominant composer nor the frontman, Fripp was very much the group's driving force and spokesman, leading them into progressively darker and more intense musical areas. McDonald and Giles, now favouring a lighter and more nuanced romantic style, became increasingly uncomfortable, and told Fripp they would be leaving the band upon the conclusion of the US tour. To keep the band together, Fripp offered to resign himself, but McDonald declared that King Crimson was "more (him) than them" and that he and Giles should therefore be the ones to leave. McDonald later said he "was probably not emotionally mature enough to handle it" and made a "rash decision to leave without consulting anyone". The original line-up played their last show at the Fillmore West in San Francisco on 14 December 1969, a little over one year after forming, with McDonald's and Giles's departures made official in January 1970. Live recordings of the band from 1969 were released in 1997 on Epitaph and in 2010 on the In the Court of the Crimson King (1969) box set. McDonald and Giles, as a spin-off duo from King Crimson, released a self-tiled album in 1971. Giles would go on to work as a session drummer, while McDonald would co-form Foreigner in 1976.
Sources: en.wikipedia.org
In horticulture, lime sulfur (lime sulphur in British English; see American and British English spelling differences) is mainly a mixture of calcium polysulfides and thiosulfate (plus other reaction by-products such as sulfite and sulfate), formed by reacting calcium hydroxide with elemental sulfur, and is used in pest control. It can be prepared by boiling a suspension of poorly soluble calcium hydroxide (lime) and solid sulfur in water, together with a small amount of surfactant to facilitate the dispersion of these solids. After elimination of residual solids (flocculation, decantation, and filtration), it is normally used as an aqueous solution, which is reddish-yellow in color and has a distinctive offensive odor of hydrogen sulfide (H2S, rotten eggs).
Chloramphenicol binds to residues A2451 and A2452 in the 23S rRNA of the ribosome and inhibits peptide bond formation. Pleuromutilins also bind to the peptidyl transferase center. Macrolide antibiotics are thought to inhibit peptidyl transferase, in addition to inhibiting ribosomal translocation.
Pappalysin-1, also known as pregnancy-associated plasma protein A, and insulin-like growth factor binding protein-4 protease is a protein encoded by the PAPPA gene in humans. PAPPA is a secreted protease whose main substrate is insulin-like growth factor binding proteins. Pappalysin-1 is also used in screening tests for Down syndrome.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.